Navigation Links
Fast-Acting, Long-Lasting Topical Relief From Arthritis Pain
Date:3/11/2009

Medicated Arthri-Zen Relief Cream(R) Clinically Shown to Work for up to 8 Hours

MIAMI, March 11 /PRNewswire/ -- Every day, 70 million Americans suffer from the aches and pains that come with arthritis and other chronic joint problems(1). One of the most effective ways to get fast relief from arthritis pain is the use of analgesic creams. The only problem is that the relief tends to be short-lived. Many people find that within 45 minutes to an hour and a half after applying a cream, the pain comes right back. RZN Nutraceuticals, www.rznnutra.com, has solved that problem, with the development of their soothing, medicated and clinically tested analgesic Arthri-Zen Relief Cream(R). A recent randomized, blinded study found that Arthri-Zen Relief Cream(R) provides fast relief that is shown to last for up to eight hours.

The study recruited 83 adults with physician-diagnosed arthritis, all of whom had had a history of daily arthritis pain for a minimum of six months. For ten days, study subjects applied Arthri-Zen Relief Cream(R) to joint "hot spots" three times a day. They were evaluated by a clinician on the first day and again on the tenth day for conditions such as arthritis, inflammation, swelling, joint stiffness, muscle pain and range of motion. Throughout the study, participants also kept daily pain diaries.

The results were eye-opening: 63% of study subjects got relief from swelling, 93.8% experienced an increase in range of motion, 94.1% got relief from arthritis and inflammation and a full 100% had relief from muscle pain and joint stiffness. All of the results were statistically significant.

However, participants didn't have to wait 10 days to feel an effect. After just five minutes, over a quarter experienced 90-100% relief from their pain. Another 41.3% got 70-89% relief. And another 22.5% had 50-69% relief. The best pa
'/>"/>

SOURCE RZN Nutraceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. NovaBay Pharmaceuticals Announces Lead Anti-infective Product Candidate, NVC-422, Shown to be Effective in Treating Topical Fungal Infection
2. ISTA Pharmaceuticals Announces Phase III Results for Once-Daily Topical Xibrom(TM) 0.09%
3. Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream
4. Topical Treatment for Cold Sores Achieves Efficacy of Oral Drugs; Represents Paradigm Shift in the Treatment of Skin Infections
5. NanoBio Demonstrates New Topical Approach to Treating Nail Fungus That Circumvents Problems with Current Therapy
6. Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
7. ImQuest Receives Two Year Phase 2 SBIR Grant to Develop Pyrimidinedione Product as an Anti-HIV Topical Microbicide
8. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Prevention of Diabetic Foot Infections
9. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers
10. Transdel Pharmaceuticals Advances Lead Topical Pain Drug into Phase 3 Program
11. MacroChem Announces Presentation of Pexiganan Phase 3 Study Results for Topical Treatment of Diabetic Foot Infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... LONDON , July 11, 2014 ... ended at 4,396.20, down 0.52%, the Dow Jones Industrial Average ... 500 closed at 1,964.68, down 0.41%. The losses were broad ... in negative. The S&P 500 Health Care Sector Index ended ... advanced 2.75% in the last one month. Investor-Edge has initiated ...
(Date:7/11/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/tjlw9k/immunoprotein ... "Immunoprotein Diagnostic Testing Market - Forecasts to 2019: ... 6% and is expected to be valued at ... http://photos.prnewswire.com/prnh/20130307/600769 ... been segmented according to immunoprotein types which include ...
(Date:7/11/2014)... LONDON , July 11, 2014 /PRNewswire/ ... of visitors to Safety & Health Expo ... by the move to London ... senior management attending exhibition.     ... (Photo: http://photos.prnewswire.com/prnh/20140711/696892-a ) ...
Breaking Medicine Technology:Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4
...   Sanofi (EURONEXT: SAN and NYSE: ... Scientific American Diabetes Association Sessions,2011, the results of three studies ... and/or,Apidra ® with the insulin delivery device,SoloSTAR ® ... of hypoglycemia vs those,using a premixed insulin product. ...
... June 24, 2011 Advanced BioHealing, Inc. ... technology in the field of regenerative medicine, today announced ... Lewin Group (Falls Church, VA) that showed the addition ... chronic diabetic foot ulcers (DFUs) resulted in a significant ...
Cached Medicine Technology:Lantus®/Apidra® SoloSTAR® Help to Improve Patient Satisfaction 2Lantus®/Apidra® SoloSTAR® Help to Improve Patient Satisfaction 3Lantus®/Apidra® SoloSTAR® Help to Improve Patient Satisfaction 4Lantus®/Apidra® SoloSTAR® Help to Improve Patient Satisfaction 5Lantus®/Apidra® SoloSTAR® Help to Improve Patient Satisfaction 6Lantus®/Apidra® SoloSTAR® Help to Improve Patient Satisfaction 7Health Economics Model Shows That Dermagraft® Combined With Conventional Care is a Cost-Effective Treatment for Diabetic Foot Ulcers in Medicare and Commercially Insured Populations 2Health Economics Model Shows That Dermagraft® Combined With Conventional Care is a Cost-Effective Treatment for Diabetic Foot Ulcers in Medicare and Commercially Insured Populations 3Health Economics Model Shows That Dermagraft® Combined With Conventional Care is a Cost-Effective Treatment for Diabetic Foot Ulcers in Medicare and Commercially Insured Populations 4Health Economics Model Shows That Dermagraft® Combined With Conventional Care is a Cost-Effective Treatment for Diabetic Foot Ulcers in Medicare and Commercially Insured Populations 5
(Date:7/12/2014)... July 12, 2014 The report, "Phthalic ... Resins) Market by Application & Geography – Trends & ... with analysis and forecasting of market volume and value. ... the derivatives separately. The market of phthalic anhydride is ... 2013 to $8,415.89 million by 2018, with a CAGR ...
(Date:7/12/2014)... In this cognitive assessment ... and training’ is defined as solution that ... enhance cognitive functions. These solutions are applied ... screening, clinical trials, driver’s safety, rehabilitation, academic ... brain training, and employers’ assessment and training ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 The fastest-growing ... for test and measurement of LTE networks continues to ... demands for smart devices have increased mobile data traffic, ... and Measurement (CT&M) market. Communications Test and Measurement equipment ... requirements. , The Communications Test and Measurement Market is ...
(Date:7/12/2014)... -- If you make exercise fun, you,ll eat less after ... adults were led on a 1.4-mile walk and were either ... walk. The participants were given lunch after the walk, and ... 35 percent more chocolate pudding for dessert than those who ... experiment, 46 adults were given mid-afternoon snacks after their walk. ...
(Date:7/12/2014)... Sean Francis, owner of the Kawartha Lakes Fit Body Boot Camp, ... also known for his support of local non-profits like the Boys ... two and is excited to announce that his fitness boot ... , The funds are the result of Francis’ 21-Day Tummy Tuck ... emails and asked his clients to put out the word that ...
Breaking Medicine News(10 mins):Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 2Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 3Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 4Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 2Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 3Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 4Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 5Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 5Health News:Make Exercise Fun, Eat Less Afterwards 2Health News:Kawartha Lakes Fit Body Boot Camp’s Successful Fat Loss Challenge Results in $2,000 to Boys and Girls Club 2Health News:Kawartha Lakes Fit Body Boot Camp’s Successful Fat Loss Challenge Results in $2,000 to Boys and Girls Club 3
... 10 Enstar Group,Limited ("Enstar") (Nasdaq: ... Enstar Australia Holdings Pty Limited, had entered ... AMP Limited ("AMP") of AMP,s,Australian-based closed reinsurance ... of AUS$585 million (approximately US$518 million)., ...
... it may cause the effect through cerebrovascular disease , ... may be associated with increased risk for mild cognitive ... University Medical Center in New York City. , Mild ... "attracted increasing interest during the past years, particularly as ...
... People rate their smiles higher than dentists do, according ... most important features of an attractive face, the study also ... with their smiles., The study, published in this months Journal ... Norway to rate their own smiles on a 100-point satisfaction ...
... Scheduled for 4:00 p.m. Eastern Time to Review Clinical, Trial ... ... the ASH Meeting, ATLANTA, Dec. 10 ... developing,novel anticancer therapeutics, presented positive results for SNS-595 in,relapsed or refractory ...
... of MGCD0103 Determined as 90 mg, * 53% of Patients ... Responses Experienced a 66% Reduction in the Risk of Death ... Compared to Non-responders, ... (TSX: MYG) today announced maturing data,from the Phase 1/2 study investigating the ...
... 10 Winners of the 2007,Award for Excellence in Human ... and Founder of the Health Improvement,Institute., Winners were: ... Online Clinical Trials Principal Investigator Self ... to educate the University,s researchers on the mechanisms by ...
Cached Medicine News:Health News:Enstar Group Limited Announces Acquisition 2Health News:Hypertension Linked to Risk of Mild Cognitive Impairment 2Health News:Sunesis Pharmaceuticals' SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology 2Health News:Sunesis Pharmaceuticals' SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology 3Health News:Sunesis Pharmaceuticals' SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology 4Health News:Sunesis Pharmaceuticals' SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology 5Health News:Sunesis Pharmaceuticals' SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology 6Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 2Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 3Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 4Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 5Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 6Health News:Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting 7Health News:2007 Human Research Protection Award Recipients Announced 2
Enhanced drug and formulary reference with integrated ID treatment guide and tools. Increase patient safety and satisfaction with our premium drug reference....
... Eppendorf Reference Series 2000 Pipette is a ... a compact and robust design, and superior ... used to operate the measuring stroke and ... Product features:Eppendorf "pipette/tip" system ensures utmost accuracy ...
... technology that makes fully integrated communication ... a reality. This advance in communication, ... levels means a significantly improved ... stays and improved outcomes. And its ...
The SJM Tailor annuloplasty ring, a fully flexible ring, is constructed of a barium-impregnated silicone strip covered with a knitted polyester sewing cuff....
Medicine Products: